Trial Search Results

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

This is a research study to test an investigational drug, Pembrolizumab (MK-3475), that has been approved for use in a certain type of melanoma; however, it has not been approved forcolorectal cancer.

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting